BidaskClub lowered shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a sell rating to a strong sell rating in a report published on Wednesday.

Several other equities analysts have also recently commented on LXRX. ValuEngine cut shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, August 17th. Citigroup dropped their target price on shares of Lexicon Pharmaceuticals from $27.00 to $26.00 and set a buy rating on the stock in a research report on Friday, November 2nd. Cowen reissued a hold rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 2nd. Gabelli reissued a hold rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 2nd. Finally, Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a strong-buy rating to a hold rating in a research report on Wednesday, November 7th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of $25.25.

NASDAQ LXRX traded down $0.05 during trading hours on Wednesday, hitting $7.39. The company’s stock had a trading volume of 15,830 shares, compared to its average volume of 401,334. Lexicon Pharmaceuticals has a 52 week low of $7.04 and a 52 week high of $13.97. The stock has a market cap of $788.09 million, a price-to-earnings ratio of -5.82 and a beta of 0.75. The company has a debt-to-equity ratio of 8.85, a quick ratio of 2.83 and a current ratio of 2.90.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. The firm had revenue of $6.90 million for the quarter, compared to analysts’ expectations of $12.56 million. During the same quarter last year, the firm earned ($0.29) EPS. The company’s quarterly revenue was down 74.3% compared to the same quarter last year. On average, sell-side analysts predict that Lexicon Pharmaceuticals will post -1.29 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tocqueville Asset Management L.P. bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth $164,000. Dynamic Technology Lab Private Ltd bought a new stake in Lexicon Pharmaceuticals in the second quarter worth $205,000. MetLife Investment Advisors LLC lifted its stake in Lexicon Pharmaceuticals by 49.8% in the third quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 11,862 shares during the last quarter. Tekla Capital Management LLC bought a new stake in Lexicon Pharmaceuticals in the third quarter worth $747,000. Finally, GSA Capital Partners LLP lifted its stake in Lexicon Pharmaceuticals by 321.7% in the third quarter. GSA Capital Partners LLP now owns 74,586 shares of the biopharmaceutical company’s stock worth $796,000 after purchasing an additional 56,900 shares during the last quarter.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: Initial Public Offering (IPO)

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.